FLT3 and acute myeloid leukemia: Furthermore, we will discuss the recent advances in targeted therapies against FLT3-mutated AML, such as first- and second-generation FLT3 inhibitors, and highlight the challenges associated with their use, including the development of resistance mechanisms.